Pyxis Oncology, Inc. (PYXS)

Every figure this model derived for PYXS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 9,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 32,996,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 36,734,000 AssetsCurrent 2026-06-30
current liabilities 27,474,000 LiabilitiesCurrent 2026-06-30
equity 11,440,000 StockholdersEquity 2026-06-30
interest expense 91,000 InterestPaidNet 2025-12-31
ocf -67,910,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 13,858,000 Revenues 2025-12-31
sbc 11,893,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PYXS on one particular measure came for.

RatioValue
cash operating margin-548.63
current ratio1.34
current ratio reported1.34
dilution pct6.33
fcf margin-490.11
interest cover-1012.15
operating margin-664.64
owner earnings margin-575.93
revenue growth-14.17
revenue growth per share-19.28
rule of 40-678.81
sbc pct revenue85.82

What to be careful about

What this model itself distrusts about PYXS's figures. Written by the derivation as it ran, not added afterwards.